CD274 and non-small cell lung carcinoma: The present study focused on concomitant drugs as clinical factors associated with poorer treatment outcomes of ICI monotherapy, providing a useful clinical biomarker in choosing ICI with or without chemotherapy for patients with advanced NSCLC with a high PD-L1 TPS.